J. Kim

发表

Neuroblastoma Originating from Extra-abdominal Sites: Association with Favorable Clinical and Biological Features

H. Koo, K. Yoo, Jhingook Kim, 2009, Journal of Korean medical science.

High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients with High-risk Stage 3 Neuroblastoma: 10-Year Experience at a Single Center

Y. Suh, H. Koo, K. Yoo, 2009, Journal of Korean medical science.

Outcome and toxicity of postoperative short course adjuvant radiation and chemotherapy following resection of adenocarcinoma of the rectum

J. Brierley, M. Moore, M. Pintilie, 2004, Acta oncologica.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcome of patients with neuroblastoma aged less than 1 year at diagnosis

H. Koo, K. Yoo, Jhingook Kim, 2009 .

A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells

J. Kim, J. E. Lee, G. Park, 2013, British Journal of Cancer.

Repeated Resection of Colorectal Cancer Pulmonary Oligometastases: Pooled Analysis and Prognostic Assessment

J. Park, M. Riquet, S. Salah, 2013, Annals of Surgical Oncology.

Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group.

K. H. Lee, C. Cho, B. Nam, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.

J. Lee, J. Kim, S. Park, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt+), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

P-C. Yang, Y. Cheng, H. Murakami, 2016 .

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

D. Planchard, P. Jänne, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.

B. K. Park, B. K. Park, T. Y. Jeon, 2015, The British journal of radiology.

Behavior of Murine Renal Carcinoma Cells Grown in Ectopic or Orthotopic Sites in Syngeneic Mice

Sung-Soo Yoon, K. Ahn, Sung-Soo Yoon, 2001, Tumor Biology.

HER-2/neu status in breast cancer The effect of chromosome 17 polysomy on

K. Kim, S. Kim, J. Kim, 2009 .

Genome‐wide genotype‐based risk model for survival in acute myeloid leukaemia patients with normal karyotype

Zhaolei Zhang, Jinny Park, E. Shin, 2013, British journal of haematology.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Gefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study.

P-C. Yang, Y. Cheng, J. Kim, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.